| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/17/2001 | DE19952956A1 Verfahren zur Verbindung von molekularen Substanzen A method for connection of molecular substances |
| 05/17/2001 | DE19943496C1 Direkt verpressbarer Rohstoff für Komprimate Directly compressible material for compressed |
| 05/17/2001 | CA2391299A1 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 05/17/2001 | CA2391278A1 Therapeutic compositions and methods of use thereof |
| 05/17/2001 | CA2390999A1 Induction of mucosal immunity by vaccination via the skin route |
| 05/17/2001 | CA2390995A1 Recombinant gelatin in vaccines |
| 05/17/2001 | CA2390834A1 Transplant/implant device and method for its production |
| 05/17/2001 | CA2390163A1 Dye labeled imidazoquinoline compounds |
| 05/17/2001 | CA2390132A1 Film coating method for tablets |
| 05/17/2001 | CA2390128A1 Pharmaceutical formulation |
| 05/17/2001 | CA2389506A1 Nucleic acid-containing complex |
| 05/17/2001 | CA2389386A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 05/17/2001 | CA2388918A1 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 05/17/2001 | CA2388643A1 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | CA2388477A1 Recombinant gelatins with uniform molecular weight |
| 05/17/2001 | CA2388044A1 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2386619A1 Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| 05/16/2001 | EP1099443A1 Transplant/implant device and method for its production |
| 05/16/2001 | EP1099385A2 Encapsulated flavour |
| 05/16/2001 | EP1098979A2 Fap alpha-specific antibody with improved producibility |
| 05/16/2001 | EP1098959A2 Medium and matrix for long-term proliferation of cells |
| 05/16/2001 | EP1098935A1 Coating and excipient agent for oral or dermal dosage forms |
| 05/16/2001 | EP1098666A2 Water-soluble drugs and methods for their production |
| 05/16/2001 | EP1098665A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 05/16/2001 | EP1098664A2 Conjugates for treating inflammatory disorders and associated tissue damage |
| 05/16/2001 | EP1098663A1 Slow release formulations comprising anionic polysaccharide |
| 05/16/2001 | EP1098660A1 Encapsulation of water soluble peptides |
| 05/16/2001 | EP1098654A1 Antilipemic composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098649A1 Method for stabilizing pharmaceutical compositions by special use of an antioxidant |
| 05/16/2001 | EP1098646A1 Stabilized carvedilol injection solution |
| 05/16/2001 | EP1098640A1 Anti-ulcer composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098637A1 Transdermal patch and topical compositions comprising propylnorapomorphine |
| 05/16/2001 | EP1098635A1 Enteric coated pharmaceutical tablet and method of manufacturing |
| 05/16/2001 | EP1098634A2 Bioenhanced formulations comprising eprosartan in oral solid dosage form |
| 05/16/2001 | EP1098633A1 Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose |
| 05/16/2001 | EP1098632A1 Charge reversal of polyion complexes |
| 05/16/2001 | EP1098628A1 Casein formulations for the delivery of bioactive constituents |
| 05/16/2001 | EP1098624A1 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type |
| 05/16/2001 | EP0996437B1 Semisolid pharmaceutical formulation containing dexketoprofen trometamol |
| 05/16/2001 | EP0982990A4 Stable liquid mineral ascorbate compositions and methods of manufacture and use |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | EP0879274B1 Technical di- and triglyceride mixtures |
| 05/16/2001 | CN1295484A Formulations for protection of PEG-interferon alpha conjugates |
| 05/16/2001 | CN1295483A Gelling ophthalmic composition containing xanthan gum |
| 05/16/2001 | CN1295479A Beta 2-adrenergic receptor agonist |
| 05/16/2001 | CN1295474A Method for stabilizing pharmaceutical composition by special use of antioxidant |
| 05/16/2001 | CN1295469A Hydroxypylcellulose and anionic polymer compositions and their use as pharmaceutical film coatings |
| 05/16/2001 | CN1295468A Modified starch coating |
| 05/16/2001 | CN1295465A Quinolone-containing liposome composition |
| 05/16/2001 | CN1295464A Solid, quick dissolving cetirizine fomulation |
| 05/16/2001 | CN1295463A Fizzy formulation |
| 05/16/2001 | CN1295462A Peroral active agent suspension |
| 05/16/2001 | CN1295456A Acidified composition for topical treatment of nail and skin conditions |
| 05/16/2001 | CN1294914A Drug composition for treatment and prevention of hepatopathy |
| 05/16/2001 | CN1065744C Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor |
| 05/15/2001 | US6232434 Polymers for delivering nitric oxide in vivo |
| 05/15/2001 | US6232304 Inclusion complexes of aryl-heterocyclic salts |
| 05/15/2001 | US6232295 Cell-specific contrast agent and gene delivery vehicles |
| 05/15/2001 | US6232293 Administering tryptophan-tryptophan, tryptophan-tyrosine, or tyrosine-tryptophan dipeptide coupled to protein or peptide carrier as antiinflammatory agent |
| 05/15/2001 | US6232287 Peptide targets prostate gland; diagnosis; drug delivery; biochemical conjugation |
| 05/15/2001 | US6232107 Nucleotide sequence coding green fluorescent protein; for use in diagnosis of microorganism infection |
| 05/15/2001 | US6232082 Vaccines |
| 05/15/2001 | US6232071 Tenascin-C nucleic acid ligands |
| 05/15/2001 | US6231892 Compositions for coating microcapsules and other surfaces |
| 05/15/2001 | US6231890 Suspension of sparingly water-soluble acidic drug |
| 05/15/2001 | US6231887 Drugs of pyranone derivatives |
| 05/15/2001 | US6231885 Composition for controlled and sustained transdermal administration |
| 05/15/2001 | US6231884 Plasters for antiischemic agents |
| 05/15/2001 | US6231881 Medium and matrix for long-term proliferation of cells |
| 05/15/2001 | US6231879 Implantable, biocompatible cell encapsulation with jackets |
| 05/15/2001 | US6231875 Acidified composition for topical treatment of nail and skin conditions |
| 05/15/2001 | US6231874 Moisturizers |
| 05/15/2001 | US6231860 Stabilizers for live vaccines |
| 05/15/2001 | US6231854 Methioninase formulations and use in diagnostic methods |
| 05/15/2001 | US6231851 Methods and compositions for the dry powder formulation of interferons |
| 05/15/2001 | US6231848 N-vinyllactam homo or copolymer complexed with hydrogen peroxide and colloidal silver or silver salt useful as prophylaxis agent |
| 05/15/2001 | US6231605 Frozen and thawed in mold to create interlocking mesh; expanded and immersed in water solution; human tissue replacement; biocompatibility |
| 05/15/2001 | CA2183268C Bispecific molecules having clinical utilities |
| 05/15/2001 | CA2158054C Conjugates of proteins and bifunctional ligands |
| 05/15/2001 | CA2154663C Polyamine derivatives as radioprotective agents |
| 05/15/2001 | CA2072355C Fibrin sealant delivery method |
| 05/15/2001 | CA2032068C Pharmaceutical lozenges |
| 05/10/2001 | WO2001033223A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | WO2001032853A1 B cell clonal toxins and methods for using the same |
| 05/10/2001 | WO2001032852A2 Method for directed packaging of molecular substances in protein shells |
| 05/10/2001 | WO2001032851A2 Modular transport systems for molecular substances and production and use thereof |
| 05/10/2001 | WO2001032751A1 Method for producing nanoparticulate chitosans or chitosan derivatives |
| 05/10/2001 | WO2001032684A2 Method for linking molecular substances based on the affinity of the proline-rich amino acid sequences and protein domains of type ww |
| 05/10/2001 | WO2001032670A1 Oxetanone derivatives |
| 05/10/2001 | WO2001032630A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | WO2001032616A2 Oxetanone derivatives |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032237A1 Method and device for preparing a medical fluid |
| 05/10/2001 | WO2001032230A2 A polymer micelle as monolayer or layer-laminated surface |
| 05/10/2001 | WO2001032224A1 Method of inactivating pathogens |
| 05/10/2001 | WO2001032222A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | WO2001032221A1 Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
| 05/10/2001 | WO2001032219A2 Treatment of c. difficile toxin b associated conditions |
| 05/10/2001 | WO2001032218A1 Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing |